About two-thirds of newly diagnosed metastatic breast cancers (MBCs) display a hormone receptor–positive, ERBB2 (also known as HER2)-negative phenotype.
1 In addition to being the principal component of breast cancer biology and genomic landscapes,
2,3 hormone receptor status was first characterized as a strong predictive factor of response to endocrine therapy.
4 In the context of hormone receptor–positive MBC, a key question therefore became whether endocrine therapy or chemotherapy, when administered as first-line therapy, would be the most beneficial treatment in terms of survival and quality of life. In 2003, a meta-analysis
5 of published data aggregated 692 patients from 6 trials conducted between 1963 and 1995; compared with up-front endocrine therapy, first-line chemotherapy yielded higher toxicity and response rates but no longer overall survival (OS). Because of the palliative context of MBC, endocrine therapy has been then established as the preferred first-line treatment of hormone receptor–positive, ERBB2-negative MBC by all expert consensus.
6-8 Experts, however, acknowledge exceptions to the systematic use of endocrine therapy as up-front therapy: patients with a rapidly evolving disease, clinically meaningful symptoms, impaired general condition, and/or life-threatening disease, commonly referred to as
visceral crisis.
9 Until recently, real-life studies repeatedly reported that chemotherapy is administered as first-line therapy in 15% to 50% of patients with hormone receptor–positive, ERBB2-negative MBC.
10-15